Title
Category
Credits
Event date
Cost
2024 Resistant gastroenteropancreatic neuroendocrine tumors: a definition and guideline to medical and surgical management
  • BUMC Proceedings
  • 1.00 American Board of Surgery (ABS) Accredited CME
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
$25.00
Gastroenteropancreatic neuroendocrine tumors (NETs), also historically known as carcinoids, are tumors derived of hormone-secreting enteroendocrine cells. Carcinoids may be found in the esophagus, stomach, small intestine, appendix, colon, rectum, or pancreas. The biologic behavior of carcinoids differs based on their location, with gastric and appendiceal NETs among the least aggressive and small intestinal and pancreatic NETs among the most aggressive. Ultimately, however, biologic behavior is most heavily influenced by tumor grade. The incidence of NETs has increased by 6.4 times over the past 40 years. Surgery remains the mainstay for management of most carcinoids. Medical management, however, is a useful adjunct and/or definitive therapy in patients with symptomatic functional carcinoids, in patients with unresectable or incompletely resected carcinoids, in some cases of recurrent carcinoid, and in postoperative patients to prevent recurrence. Functional tumors with persistent symptoms or progressive metastatic carcinoids despite therapy are called “resistant” tumors. In patients with unresectable disease and/or carcinoid syndrome, an array of medical therapies is available, mainly including somatostatin analogues, molecular-targeted therapy, and peptide receptor radionuclide therapy. Active research is ongoing to identify additional targeted therapies for patients with resistant carcinoids.
2024 The effect of polycystic ovarian syndrome on fibrocystic breast changes in postmenopausal women
  • BUMC Proceedings
  • 1.00 American Board of Internal Medicine (ABIM) MOC Part 2
  • 1.00 American Board of Surgery (ABS) Accredited CME
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
$25.00
AbstractFibrocystic breast changes (FCCs) are benign lesions thought to be caused by an increased estrogen-to-progesterone ratio. One of the most common endocrinopathies that increases this ratio is polycystic ovarian syndrome (PCOS). Although nonproliferative FCCs do not increase the risk of breast cancer, they can make mammographic detection of malignancy in postmenopausal women more difficult. The aim of this study was to investigate the effects of PCOS on the development of postmenopausal FCCs.
2024 The efficacy and safety of botulinum toxin epicardial fat injection to prevent postoperative atrial fibrillation in patients undergoing cardiac surgery: a meta-analysis of randomized controlled trials
  • BUMC Proceedings
  • 1.00 American Board of Internal Medicine (ABIM) MOC Part 2
  • 1.00 American Board of Surgery (ABS) Accredited CME
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
$25.00
Postoperative atrial fibrillation (POAF) is prevalent in about 30% to 60% of patients undergoing cardiac surgery, leading to worse outcomes. Botulinum toxin type A (BTX) epicardial injection has been proposed to prevent POAF by impairing cholinergic signaling.